Advanced Prostate Cancer Patients Do Not Benefit from Reolysin, Taxotere Combo, Trial Shows
News
Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial. The trial (NCT01619813) failed to meet ... Read more